Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, phase II/III dose-finding study with a PK/PD characterisation and a 1 year efficacy/safety evaluation.

Trial Profile

Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, phase II/III dose-finding study with a PK/PD characterisation and a 1 year efficacy/safety evaluation.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure; Dilated cardiomyopathy
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 30 Sep 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 17 Mar 2012 Additional lead trial investigator identified as reported by United Kingdom Clinical Research Network.
    • 17 Mar 2012 New source identified and integrated (United Kingdom Clinical Research Network; 10291).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top